Systems biology and microbiome innovations for personalized diabetic retinopathy management
Javad Aminian-Dehkordi1, Fateme Montazeri2, Ali Tamadon1
1Molecular Cell Biomechanics Laboratory, Departments of Bioengineering and Mechanical Engineering, University of California, Berkeley, CA, USA.
Abstract:
Diabetic retinopathy (DR), a complex condition driven by inflammation, oxidative stress, and metabolic imbalances, calls for innovative treatment strategies. Engineered probiotics delivering angiotensin-converting enzyme 2 (ACE2) offer a promising strategy by leveraging gut microbiome-retina association. Advances in synthetic biology and computational techniques enable personalized, data-driven therapies. This review discusses computational approaches at multiple scales and presents an integrated framework for promoting personalized, systems-level DR management.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Microorganisms in Medicine and Therapeutics


